TY - JOUR
T1 - Bioequivalence study of 2 orodispersible formulations of ondansetron 8 mg in healthy volunteers
AU - Cánovas, M.
AU - Rios, J.
AU - Domenech, G.
AU - Cebrecos, J.
AU - Pelagio, P.
AU - Canals, M.
AU - Polonio, F.
AU - Cabré, F.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - This study was designed to compare the rate and extent of absorption of 2 oral formulations of ondansetron (CAS 99614-02-5) 8 mg orodispersible tablets in healthy volunteers. 22 subjects were administered ondansetron orodispersible tablets of test and reference formulation in a single-dose, 2-period, 2-sequence, fasting, open-label, crossover and randomised study. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUCs and C max values were tested for bioequivalence based on the ratios of the geometric means (test/reference). T max was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC 0-t and C max were within the bioequivalence acceptance range of 80-125%. According to the European Guideline [1] it may be therefore concluded that test formulation of ondansetron 8 mg orodispersible tablet is bioequivalent to the reference formulation. © Georg Thieme Verlag KG · Stuttgart · New York.
AB - This study was designed to compare the rate and extent of absorption of 2 oral formulations of ondansetron (CAS 99614-02-5) 8 mg orodispersible tablets in healthy volunteers. 22 subjects were administered ondansetron orodispersible tablets of test and reference formulation in a single-dose, 2-period, 2-sequence, fasting, open-label, crossover and randomised study. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUCs and C max values were tested for bioequivalence based on the ratios of the geometric means (test/reference). T max was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC 0-t and C max were within the bioequivalence acceptance range of 80-125%. According to the European Guideline [1] it may be therefore concluded that test formulation of ondansetron 8 mg orodispersible tablet is bioequivalent to the reference formulation. © Georg Thieme Verlag KG · Stuttgart · New York.
KW - antiemetic
KW - bioequivalence
KW - CAS 99614-02-5
KW - ondansetron
KW - pharmacokinetics
UR - https://www.scopus.com/pages/publications/84859922153
U2 - 10.1055/s-0031-1295488
DO - 10.1055/s-0031-1295488
M3 - Article
C2 - 22344549
SN - 0004-4172
VL - 62
SP - 59
EP - 62
JO - Arzneimittel-Forschung/Drug Research
JF - Arzneimittel-Forschung/Drug Research
IS - 2
ER -